Συγγραφικό – Επιστημονικό έργο

ΣΥΓΓΡΑΦΙΚΗ ΕΜΠΕΙΡΙΑ

Referee in American Journal of Cardiology, Journal of American College of
Cardiology and Journal of Catheterization and cardiovascular Diagnosis.

 

ΔΗΜΟΣΙΕΥΣΕΙΣ ΜΕ ΣΥΣΤΗΜΑ ΚΡΙΤΩΝ

Karagounis L, Ipsen SK, Jessop MR, Gilmore KM, Valenti DA, Clawson JJ, Anderson JL, for the FAST-MI, Phase I study. Impact of field-transmitted electrocardiography on time to in-hospital thrombolytic therapy in acute myocardial infarction. Am J Cardiol 1990; 66:773-778.

2. Freedman RA, Steinberg JS for the ESVEM Investigators*. Selective prolongation of QRS late potentials by sodium channel blocking antiarrhythmic drugs: relation to slowing of ventricular tachycardia. J Am Coll Cardiol 1991; 17:1017-25.

3. Anderson JL, Sorensen SG, Moreno F, Hackwothy RA, Browne KF, Dale HT, Leya F, Dangoisse V, Eckerson HW, Marder VJ, and the TEAM-2 Study Investigators*. Multicenter patency trial of intravenous anistreplase compared with streptokinase in acute myocardial infarction. Circulation 1991; 83:126-140.

4. The TAMI-5 Study Group*. Evaluation of combination thrombolytic therapy and timing of cardiac catheterization in acute myocardial infarction. Circulation 1991; 83:1543-1556.

5. Anderson JL, Karagounis L, Allen A, Bradford MJ, Pryor TA. Age and systolic hypertension are risk factors for intracranial hemorrhage after thrombolysis. Am J Card 1991; 68:166-170.

6. Karagounis L, Ipsen S, Moreno FL, Menlove RL, Anderson JL, and the TEAM-2 Investigators. Effects of early thrombolytic therapy on enzymatic and electrocardiographic infarct size: results of a randomized, blinded study of anistreplase versus streptokinase in myocardial infarction. Am J Card 1991;68:848-56

7. Karagounis L, Sorensen S, Moreno FLL, Menlove RL, Anderson JL, and the TEAM-2 Investigators. Does TIMI grade 2 perfusion represent a mostly patent artery or a mostly occluded artery? enzymatic and electrocardiographic evidence from the TEAM-2 Study. J Am Coll Cardiol 1992;19:1-10.

8. Anderson JL, Becker LC, Sorensen S, Karagounis L, Moreno FLL, Browne KF, Shah PK, Morris DC, Fintel DJ, Mueller HS, Ross AM, Hall SM, Askins JC, Doorey AJ, Grines CL, Marder NJ, for the TEAM-3 Investigators. Anistreplase versus alteplase in acute myocardial infarction: comparative effects on left ventricular function, 1 day patency, and morbidity: the TEAM-3. J Am Coll Cardiol 1992;20:753-66.

9. Moreno FLl, Karagounis LA, Marsall H, Menlove RL, Ipsen S, and Anderson JL. Thrombolysis related early patency reduces electrocardiographic late potentials after acute myocardial infarction. Am Heart J 1992; 124:557-564.
Moreno FLl, Summers KL, Menlove RL, Claypool W, Cox JR, Karagounis L, and Anderson JL. Clinical evaluation of bidisomide, a promising new class I antiarrhythmic: initial intravenous dose-finding study. Drug Development Research 1992; 27:239-252.

11. Topol EJ, for the TAMI-6 Study Group*: A randomized trial of late reperfusion therapy for acute muocardial infarction. Circulation 1992; 85:2090-2099.

12. ISIS-3 (Third International Study of Infarct Survival) Collaborative Group*. ISIS-3 a 00randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction. Lancet 1992;8796:753-770.

13. Freedman RA, Karagounis LA, Greenberg GM, Steinberg JS and the technical assistance of Crowell AJ, Moddrelle DS, Krall RC. Effects of sotalol on the signal-averaged ECG in patients with sustained ventricular tachycardia: relation to suppression of inducibility and changes in tachycardia cycle length. J Am Coll Cardiol 1992;1213-9.

14. Stein KM, Karagounis LA, Anderson JL and Kligfield P. Day-to-day reproducibility of two fractal measures of VPC clustering. Computers in Medicine. October 1992.

15. Popma JJ, Anderson JL, and the TAMI-5 Investigators*. Mechanism of benefit of combination thrombolytic therapy for acute myocardial infarction: a quantitative angiographic and hematologic study. J Am Cardiol 1992;1305-12.

16. The TIMI-3A Investigators*. Early effects of tissue plasminogen activator, added to conventional therapy, on the culprit coronary lesion in patients presenting with unstable angina. Results if the Thrombolysis in Myocardial Ischemia (T-3A) Trial. Circulation 1993;87:323-327.

17. The Electrophysiologic Study versus Electrocardiographic Monitoring Investigators*. Determinants of predicted efficacy of antiarrhythmic drugs in the ESVEM trial. Circulation 1993;87:323-327.

18. Anderson JL, Karagounis LA, Sorensen SG, Menlove RL, for the TEAM-3 Investigators. TIMI perfusion grade 3 but not grade 2 results in improved outcome after myocardial infarction: ventriculographic, enzymatic and electrocardiographic evidence from TEAM-3 Study. Circulation 1993;87:1826-1839.

19. Mason JW for the Electrophysiologic Study versus Electrocardiographic Monitoring Investigators*. Comparison of electrophysiologic study to electrocardiographic monitoring for prediction of antiarrhythmic drug efficacy in patients with ventricular tachyarrhythmias. N Engl J Med 1993;329:445-51.

20. Mason JW for the Electrophysiologic Study versus Electrocardiographic Monitoring Investigators*. Relative efficacy of antiarrhythmic drugs in the ESVEM Trial. N Engl J Med 1993;329:442-8.

21. Gomez MG, Karagounis LA, Allen A, Anderson JL, for the TEAM-2 Investigators. Effect of cigarette smoking on patency after thrombolytic therapy for myocardial infarction. J Am Cardiol 1993;72:373-378.

22. LATE Study Group*. Late assessment of thrombolytic efficacy (LATE) study with alteplase 6-24 hours after onset of acute myocardial infarction. Lancet 1993; 342:759-766.

23.Karagounis LA, Anderson JL, Sorensen SG, Moreno FLl for the TEAM-3. Relation of reperfusion success with anistreplase or alteplase in acute myocardial infarction to body weight. Am J Cardiol 1994; 73:16-22.

24. Marsall HW, Morrison L, Wu L, Anderson JL, Corneli P, Stouffer D, Allen A, Karagounis LA, Ward RH. Apolipoprotein polymorphisms fail to define risk of coronary artery disease: results of a prospective, angiographically controlled study. Circulation 1994; 89:567-577.

25. Anderson JL, Karagounis LA, Osborn JS, Roskelley M, and Handrahan D. A randomized comparison of antiarrhythmic therapy versus no therapy on time to implantable defibrillator discharge in patients with ventricular tachycardia. J Am Cardiol 1994;73:683-687.

26. Cannon CP, McCabe CH, Henry TD, Schweiger MJ, Gibson RS, Mueller HS, Becker RC, Kleiman NS, Haugland JM, Anderson JL, Sharaf BL, Edwards SJ, Rogers WJ, Williams DO, Braunwald E, for the TIMI-5 Investigators*. A pilot trial of recombinant desulfatohirudin compared to heparin in conjunction with tissue plasminogen activator and aspirin for acute myocardial infarction: Results of the thrombolysis in myocardial infarction (TIMI) 5 trial. J Am Coll Cardiol 1994; 23:993-1003.

27. The TIMI IIIB Investigators*. Effects of tissue plasminogen activator and a comparison of early invasive an conservative strategies in unstable angina and non-Q-wave myocardial infarction. Circulation 1994; 89:1545-1556.

28. Moreno Ll, Villanueva MT, Karagounis LA, Anderson JL for the TEAM-2 Study Investigators. Reduction in QT interval dispersion by successful thrombolytic therapy in acute myocardial infarction. Circulation 1994; 90:94-100.

29. The TIMI IIIB Investigators*. Effects of tissue plasminogen activator and a comparison of early invasive an conservative strategies in unstable angina and non-Q-wave myocardial infarction. Circulation 1994; 89:1545-1556.

30. Weaver WD, Hartmann JR, Anderson JL, Reddy PS, Sobolski JC, Sasahara AA, for the Prourokinase Study Group*. A new recombinant glycosylated prourokinase for treatment of patients with acute myocardial infarction. J Am Coll Cardiol 1994; in press.

31. Cannon CP, McCabe CH, Diver DJ, Herson S, Greene RM, Shah PK, Sequeira RF, Leya F, Kirshenbaum JM, Magorien RD, Palmeri ST, Davis V, GIbson CM, Poole WK, Braunwald E, and the TIMI 4 Investigators*. A comparison of front-loaded tissue-type plasminogen activator, anistreplase and combination thrombolytic therapy for acute myocardial infarction: Results of the thrombolysis in myocardial infarction (TIMI) 4 trial. J Am Coll Cardiol 1994; 24:1602-1610.

32. Antman EM, for the TIMI 9A Investigators*. Hirudin in acute myocardial infarction safety report from the thrombolysis and thrombin inhibition in myocardial infarction (TIMI) 9A trial.Circulation 1994; 90:4 1624-1630.

33. Karagounis LA, Anderson JL, Allen A, and Osborn JL. Drug-related increases in ventricular refractoriness predicts success, and increases in conduction time predict drug failure in patients undergoing programmed electrical stimulation. A Heart J 1995;129:343-9.

34. Sung RJ, Tan HL, Karagounis LA, Hanyok JJ, Das G, Falk R, Platia E, Hardy S, and the Sotalol Multicenter Study Group. Intravenous sotalol for the termination of supraventicular tachycardia and atrial fibrillation / flutter: amulticenter, randomized, double blind, placebo-controlled study. Am Heart J 1995; 129:739-748.

35. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group*. ISIS-4 A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Lancet 1995; 345:669-685.

36. The AVID Investigators*. Aantiarrhythmics versus implantable defibrillators (AVID)-rationale, design and methods. Am J Cardiol 1995; 75:47.

37. Stein MK, Karagounis LA, Anderson JL, Kligfield P, Lerman BB. Fractal clustering of ventricular ectopy correlates with sympathetic tone preceding ectopic beats. Circulation 1995;91:722-28.

38. Zahger D, Karagounis LA, Cercek B, Anderson JL, Sorensen SG, Moreno FL and Shah PK. Incomplete recanalization as an important determinant of TIMI-2 flow after thrombolytic therapy for acute myocardial infarction. Am J Cardiol 1995;76:749-52.

39. Kowey PR, Levine JH, Herre JM, Pacifico A, Linday BD, Plumb VJ, Janosik DL, Kopelman HA, Sheinman MM, for the Intravenous Amiodarone Multicenter Investigators Group*. Circulation 1995;92:3255-63.

40. Karagounis LA, Stein KM, Afridi SN, Bair T, Albright D, and Anderson JL. Investigators. Fractal dimension predicts arrhythmia recurrence in patients being treated for life threatening ventricular arrhythmias. Journal of Electrocardiology 1995;28:71-73.

41. Muhlestein JB, Hammond EH, Carlquist JF, Radicke E, Thomson MJ, Karagounis LA, Woods M and Anderson JL. Increased incidence of chlamydia species within coronary arteries of patients with symptomatic atherosclerotic versus other forms of cardiovascular disease. J Am Coll Cardiol 1996; 27:1555-61.

42. Anderson JL, Karagounis LA and Califf RM. Association of early coronary patency grades with mortality and clinical outcomes after myocardial infarction: results of a metaanalysis of published studies. Am J Cardiol 1996;78:1-8.

43. Gomez MA, Anderson JL, Karagounis LA, Muhlestein JB, Moores FB, for the ROMIO Study Group. An emergency department based protocol for rapid rule-out of myocardial ischemia reduces time and expense: results of a randomized study (ROMIO). J Am Coll Cardiol 1996;28:25-33.

44. Anderson JL, Pratt GM, Waldo AL, and Karagounis LA. The impact of the FDA approval of flecainide and encainide on coronary heart disease mortality: putting «deadly medicine» to the test. Am J Cardiol 1997;79:43-47.

45. Reiter MJ, Karagounis LA, Mann DE, Reiffel JE, Hahn E, Hartz V, and the ESVEM Investigators. Reproducibility of drug efficacy by Holter monitoring in the electrophysiologic study versus electrocardiographic monitoring (ESVEM) trial Am J Cardiol 1997;79:315-322.

46. Anderson JL, Karagounis LA, Stein KM, Moreno FL, Ledingham R, Hallstrom A for the CAST Investigators. Predictive value for future arrhythmic events of fractal dimension, a measure of time-clustering of ventricular premature complexes, after myocardial infarction. J Am Coll Cardiol 1997;30:226-32.

47. The atrial fibrillation investigation with bidisomide (AFIB) Investigators*. Treatment of atrial fibrillation and paroxysmal supraventricular tachycardia with bidisomide. Circulation 1997;96:2625-2632.

48. Karagounis LA, Anderson JL, Sorensen SG, Moreno FLl for the TEAM-3. Multivariate associates of QT dispersion in patients with acute myocardial infarction: primacy of patency status of the infarct related artery. To be published in Am Heart J 1997.

49. Muhlestein JB, Wardeh A, Karagounis LA, Trehan S and Anderson JL. Rescue utilization of abciximab for the dissolution of coronary thrombus developing as a complication of coronary angioplasty. To be published in J Am Coll Cardiol 1997.

50. Stein MK, Karagounis LA, Anderson JL and Lerman BB. Autonomic triggers of ventricular tachycardia: reentry vs triggered activity. Submitted to Circulation.

51. Karatasakis GT, Karagounis LA, Kalyvas PA, Manginas A, Athanassopoulos GD, Aggelakas SA and Cokkinos DV. The importance of right ventricular function in predicting outcome in patients with advance heart failure. Submitted to J Am Coll Cardiol.

52. Anastasiou-Nana MI, Karagounis LA, Anderson JL, Mason JW and the ESVEM Investigators. Spontaneous variability of ventricular ectopic activity in patients with sustained ventricular tachycardia and in survivors of cardiac arrest. Submitted.

53. Karagounis LA, Anderson JL and the TEAM-2 Investigators. Circadian variation of thrombolysis. In preparation.

*Member of multicenter study group

 

Εργασίες κατόπιν πρόσκλησης

  1. Anderson JL, Gomez MG, and Karagounis LA. Very early thrombolysis for acute myocardial Infarction. Challenges of thrombolytic therapy. Editor: HJC Swan, MD, PhD. Am J Cardiol 1993.2. Anderson JL, Karagounis LA. Does intravenous heparin or time-to-treatment reperfusion explain differences between GUSTO and ISIS-3 results? (Editorial). Am J Cardiol 1994; 74:1057-1060.

Κεφάλαια Βιβλίων

  1. Lessons from the large thrombolytic trials. Karagounis LA. In Cardiovascular Diseases. Editor Cokkinos DV (in press Greek language).

Δημοσιεύσεις με σύστημα κριτών με κρίση στην περίληψη

  1. Troyer P, Lui C, Karagounis L, Chakko S. University of Virginia Affiliated Hospitals Program, Roanoke-Salem, Virginia. Prediction of severe proximal stenosis of the left anterior descending artery by electrocardiogram. Presented at National AFCR, 1988.2. Karagounis L, Ipsen SK, Jessop MR, Gilmore KM, Valenti DA, Clawson JJ, Anderson JL. Impact of field-transmitted electrocardiography on time to in-hospital thrombolytic therapy in acute myocardial infarction. Circulation1989; 80II-118(475).3. Karagounis L, Fang G, Allen A, Parker D, Frederick P, Hugl B and Anderson JL. Early detection of coronary artery calcification by ultrafast cine computed tomography: a new noninvasive test to detect early coronary artery disease. Presented in the Utah Scientific Meetings of American College of Physicians. September 14 1990. Salt Lake City, Utah.4. Califf RM, Topol EJ, George BS, Kereiakes DJ, Samaha JK, Worley SJ, Anderson J, Sasahara A, Lee K, Stack RS. TAMI-5*: a randomized trial of combination thrombolytic therapy and immediate cardiac catheterization. Circulation 1989; 80:II-418(1660).5. Anderson JL, Hackwothy RA, Sorensen SG, Moreno F, Browne KF, Dale HT, Leya F, Dangoisse V, Marder VJ, and the TEAM Study Investigators*. Comparison of intravenous anistreplase (APSAC) and streptokinase in acute myocardial infarction: interim report of a randomized, double-blind patency study. Circulation 1989;80:II-420(1669).6. Whitlow PL for the CRAFT Study Group*. Catheterization/ rescue angioplasty following thrombolysis (CRAFT) study: results of rescue angioplasty. Circulation 1990; 82:II-308(1222).

    7. Whitlow PL for the CRAFT Study Group*. Catheterization/ rescue angioplasty following thrombolysis (CRAFT) study: acute myocardial infarction treated with recombinant tissuetype plasminogen activator (rt-PA) versus urokinase (UK). JACC 1991; 12:2 227A

    8. Whitlow PL for the CRAFT Study Group*. Catheterization/ rescue angioplasty following thrombolysis (CRAFT) study: effect of recombinant tissue plasminogen activator (rt-PA) versus urokinase (UK) on ventricular function less than 2 hours after acute myocardial infarction. Circulation 1990; 82:III-377(1495).

  2. Anderson JL, Karagounis L, Allen A, Bradford MJ, Pryor TA. Age and systolic hypertension are risk factors for intracranial hemorrhage after thrombolysis. Circulation 1990; 2:II-665(2642)10. Karagounis L, Ipsen S, Moreno FL, Anderson JL, and the TEAM-2 Investigators. Anistreplase versus streptokinase in myocardial infarction: effects on enzymatic and electrocardiographic indices. Circulation 1990; 82:II-665(2642).11. Feit F, Breed J, Anderson JL, Atubaro MJ, Davison R, Sherrid MV, Teichman S, and the TTOPP Group*. A randomized, placebo-controlled, trial of tissue plasminogen activator in elderly patients with acute myocardial infarction. Circulation 1990; 82:II-666(2647).12. Anderson JL, Sorensen SG, Moreno F, Hackwothy RA, Browne KF, Dale HT, Leya F, Dangoisse V, Marder VJ, and the TEAM-2 Study Investigators*. Quantitative assessment of coronary stenosis after thrombolysis in acute myocardial infarction: results of a randomized study of anistreplase and streptokinase. J Am Coll Cardiol 1990; 15:218(A).13. Califf RM, for the TAMI Study Group*. In-hospital clinical outcomes in the TAMI-5 study. J Am Coll Cardiol 1990; 15:76A.14. Topol EJ, Ellis SG, Wall TC, George BS, Vandormael M, Grines CL, Sanz ML, O’ Brien M, Calliff RM, for the TAMI-6 Study Group*: A randomized, controlled trial of late (6-24 hour) reperfusion for acute myocardial infarction. Circulation 1990; 82:III-539 (2139).

    15. Gomez MA, Karagounis L, Allen A, and Anderson JL. Pre-hospital (paramedic trial of tissue plasminogen activator for acute myocardial infarcion. Pilot phase of the FAST-MI (field alteplase study of thrombolysis in myocardial infarction). Presented in the Utah Scientific Meetings of American College of Physicians. September 13 1991. Salt Lake City, Utah.

    16. Topol EJ, Ellis SG, Wall TC, George BS, Vandormael M, Grines CL, Sanz ML, O’ Brien M, Calliff RM, for the TAMI-6 Study Group*: Does late reperfusion for myocardial infarction improve left ventricular function? Preliminary results of the TAMI-6 randomized, controlled trial. J Am Coll Cardiol 1991; 17:45A.

    17. Brown BG for the TIMI-III Investigators*. TIMI-IIIA Trial: Results and Discussion. Symposium presentation at the 40th Annual Scientific Session, American College of Cardiology. March 5, 1991, Atlanta, Georgia.

    18. Sleight P: ISIS-3 Trial*: Results of SK vs APSAC vs TPA. Symposium presentation at the 40th Annual Scientific Session, American College of Cardiology. March 5, 1991, Atlanta, Georgia.

    19. Anderson JL, Becker LC, Morris DC, Shah PK, Browne KF, Fintel DJ, Askins JC, Doorey A, Ross AM, and the TEAM-3 Investigators*. Comparison of anistreplase and alteplase in myocardial infarction: preliminary report of the TEAM-3 study. J Am Coll Cardiol 1991.

    20. Fears R, Hearn J, Standring R, Anderson JL, and the TEAM-2 Investigators. Pre-treatment anti-streptokinase antibody levels do not influence coronary patency achieved by anistreplase and streptokinase. J Am Coll Cardiol 1991; 17:153A.

    21. Moreno FLl, Karagounis L, Ipsen S, Marshall H, Anderson JL. Thrombolysis related early reperfusion reduces ECG late potentials after acute myocardial infarction. J Am Coll Cardiol 1991; 17(A):312A.

    22. Steinberg JS, Prystowsky E, Freedman RA, Moreno FLl, Katz R, Kron J, Regan A, and the Multicenter Signal-Averaged ECG Study Group*. Usefulness of the signal averaged ECG for predicting inducible ventricular tachycardia in patients with unexplained syncope. J Am Coll Cardiol 1991; 17(A):98A.

    23. Anderson JL, Becker LC, Browne KF, Shah PK, Morris DC, Fintel DJ, Mueller HS, Ross AM, and the TEAM-3 Investigators. A double blind, randomized comparison of anistreplase (APSAC) and alteplase (tPA) in acute myocardial infarction: functional and morbidity results. Circulation 1991; 84:II-571 (2270).

    24. TheElectrophysiologic Study versus Electrocardiographic Monitoring Investigators*. Determinants of a drug efficacy prediction in the ESVEM Trial: differences between electrophysiological study (EPS) and Holter monitoring (HM). Circulation 1991; 84:II-348 (1385).

    25. Mason JW and the Electrophysiologic Study versus Electrocardiographic Monitoring Investigators*. Unsustained VT as a predictor of spontaneous sustained VT in the ESVEM Study. Circulation 1991; 84:II-348 (1386).

    26. Karagounis L, Sorensen S, Moreno F, Menlove RL, Anderson JL, and the TEAM-2 Investigators. Does TIMI grade 2 perfusion represent a mostly patent artery or a mostly occluded artery? enzymatic and electrocardiographic evidence from the TEAM-2 Study. Circulation 1991; 84:II-115 (459).

    27. Marshall HW, Morrison L, Karagounis L, Corneli P, Stouffer D, Allen A, Anderson JL and Ward RH. Genetic sreening for risk of coronary disease: prospectus. J Am Coll Cardiol 1992; 19(A):150A.

    28. Anderson JL, Moreno FLI, Karagounis L, Menlove RL, Stein KM, Bigger JT, for the CAPS Investigators. Fractal clustering of ventricular arrhythmias as a predictor of arrhythmic events after myocardial infarction. J Am Coll Cardiol 1992; 19(A):265A.

    29. Karagounis L, Menlove RL, Anderson JL, for the TEAM-3 Investigators. Does reperfusion depend on body weight? Results of a randomized comparison of Anistreplase (APSAC) and Alteplase (t-PA). J Am Coll Cardiol 1992; 19(A):275A.

    30. Anderson JL, Karagounis LA, Sorensen SG, Menlove RL, for the TEAM-3 Investigators. TIMI perfusion grade 3 but not grade 2 results in improved outcome after myocardial infarction: ventriculographic, enzymatic and electrocardiographic evidence from TEAM-3 Study. J Am Coll Cardiol 1992; 19(A):275A.

    31. Karagounis LA, Stein KM, Menlove RL, Anderson JL. Variability and predictive value of fractal D for future events in patients with life threatening arrhythmias. J Am Coll Cardiol 1992; 19(A):366A.

    32. Mason JW for the Electrophysiologic Study versus Electrocardiographic Monitoring Investigators*. Preliminary results of the Electrophysiologic Study versus Electrocardiographic Monitoring (ESVEM) Trial: Accuracy of Electrophysiologic Study vs Holter Monitoring in predicting ventricular tachyarrhythmia prevention. Symposium presentation at the 41th Annual Scientific Session, American College of Cardiology. April, 1992, Dallas, Texas.

    33. Marcus FI for the Electrophysiologic Study versus Electrocardiographic Monitoring Investigators*. Preliminary results of the Electrophysiologic Study versus Electrocardiographic Monitoring (ESVEM) Trial: Relative efficacy of seven antiarrhythmic drugs in prevention of ventricular tachyarrhythmias. Symposium presentation at the 41th Annual Scientific Session, American College of Cardiology. April, 1992, Dallas, Texas.

    34. Sung RJ, Karagounis LA, Gopas D, Falk R, Platia E, Hanyok J, Archibald D, and the Sotalol Multicenter Group. Intravenous Sotalol for the treatment of supraventricular tachyarrhythmias: safety and efficacy. J Am Coll Cardiol 1992; 19(A):220A.

    35. The Electrophysiologic Study versus Electrocardiographic Monitoring Investigators*. Incidence of drug efficacy in the Electrophysiologic Study versus Electrocardiographic Monitoring (ESVEM) Trial. J Am Coll Cardiol 1992; 19(A):387A.

    36. Anderson JL, Karagounis LA, Osborn JS. What electrophysiologic effects of antiarrhythmic drug therapy predict successful suppression of induced ventricular tachyarrhytmia? Presented in European Society of Cardiology, August 1992. Barcelona, Spain.

    37. Gomez MA, Karagounis LA, Allen A, and Anderson JL. Does an allergic-type reaction to streptokinase or anistreplase affect patency status following thrombolysis for acute myocardial infarction? Presented in the Utah Scientific Meetings of American College of Physicians. September 1992. Salt Lake City, Utah.

    38. Stein KM, Karagounis LA, Anderson JL and Kligfield P. Day-to-day reproducibility of two fractal measures of VPC clustering. Computers in Medicine. October 1992.

    39. Moreno FLl, Karagounis LA, Villanueva T, Horn SD, and Anderson JL. Comparison of signal-averaged electrocardiographic systems for detection of late potentials in 104 normal subjects. 12th Annual Marquette ECG Analysis Seminar October 18-20, 1992, Islamorada, Florida.

    40. Braunwald E. TIMI-V*: Hirudin vs heparin with lytic therapy in acute MI. Presented in the Eighth International Workshop in Thrombolysis and Interventional Therapy in Acute Myocardial Infarction. November 1992. New Orleans, Louisiana.

    41. Gomez MA, Karagounis LA, Allen A, and Anderson JL. Is cigarette smoking an independent predictor of improved patency after lytic therapy for myocardial infarction? Circulation 1992; 84:I-115 (459).

    42. Diver DJ, Bier JD, Williams DO, McCabe C, Braunwald E, and the TIMI-3A Study Group*. Characterization of patients angiographically excluded from TIMI-3A Trial. Circulation 1992; 84:I-454 (1810).

    43. Moreno FLl, Karagounis LA, and Anderson JL for the TEAM-2 Study Investigators. Reduction in QT interval dispersion by successful thrombolytic therapy in acute myocardial infarction. Circulation 1992; 84:I-567 (1566).

    44. Anderson JL, Karagounis LA, Osborn JS, Roskelley M, and Handrahan D. A randomized comparison of antiarrhythmic therapy versus no therapy on time to implantable defibrillator discharge in patients with ventricular tachycardia. Circulation 1992; 84:I-655 (2608).

    45. Allen A, Karagounis LA, Roskelley M, Summers K, and Anderson JL. Does entry into thrombolysis trials adversely affect time-to-treatment? a comparison of study and non-study patients. Associates of Clinical Pharmacology. Annual Meeting, March 24-26, 1993.

    46. Anderson JL, Gomez MA, and Karagounis LA, Does allergic-type reaction to streptokinase or anistreplase affect patency status following thrombolysis for acute myocardial infarction? J Am Coll Cardiol 1993; 19(A):348A.

    47. Cannon CP, McCabe CH, Henry TD, Rogers WJ, Schweiger M, Gibson RS, Anderson JL, Williams DO, Braunwald E for the TIMI 5* Investigators. Hirudin reduces reocclusion compared to heparin following thrombolysis in acute myocardial infarction: results of the TIMI-5 trial. J Am Coll Cardiol 1993; 19(A):136A.

    48. Weaver WD, Reddy PS, Anderson JL Hartmann JR, for the r-proUK Study Group*. Initial human studies of A-74187, r-proUK: a new rapidly acting thrombus-specific thrombolytic agent. J Am Coll Cardiol 1993; 19(A):397A.

    49. Corneli PS, Wu L, Marsall HW, Karagounis LA, Allen A, Ward RH. Sex-specific effects of lipoprotein (a) on the risk of coronary artery disease. J Am Coll Cardiol 1993; 19(A):226A.

    50. Karagounis LA, Anderson JL, Becker LC. Does chronic ischemic preconditioning limit infarct size in patients treated with fibrinolytics for acute myocardial infarction? J Am Coll Cardiol 1993; 19(A):150A.

    51. Eisenberg PR, Abendschein DR, Becker RC, Loscalzo J, Sobel BE, and the TIMI 5* Investigators. Lack of suppression of thrombin activity in vitro: a determinant of failure of recanalization. J Am Coll Cardiol 1993; 21(A):464A.

    52. Karagounis LA , Anderson JL, Allen A, and Osborn JS. Drug-related increases in ventricular refractoriness predict success, and increases in conduction time predict drug failure in patients undergoing programmed electrical stimulation. Clinical Research. 1993; 41:118A April 30th 93, Washington DC.

    53. Omoigui N, Marcus F, Mason J, Hlatky M for the Electrophysiologic Study versus Electrocardiographic Monitoring Investigators*. Effect of clinical and technical variables on initial hospital cost in ESVEM. Clinical Research. 1993; 41:120A April 30th 93, Washington DC.

    54. Omoigui N, Marcus F, Mason J, Hlatky M for the Electrophysiologic Study versus Electrocardiographic Monitoring Investigators*. Initial hospital costs in ESVEM. Clinical Research. 1993; 41:234A April 30th 93, Washington DC.

    55. Cannon CP, McCabe CH, Diver DJ, Herson S, Greene RM, Shah PK, Sequeira RF, Leya F, Kirshenbaum JM, Magorien RD, Palmeri S, Dangoisse V, Flaker GC, Davis V, Bhaltman B, Wackers FJTh, Zaret BL, Gibson CM, Poole WK, Braunwald E, for the TIMI 4 Investigators*. Clinical benefit of front-loaded tPA over combination thrombolytic therapy or APSAC for acute MI: Results of the TIMI-4 trial. Circulation 1993; 88:I-291(1556).

    56. Moreno FLl, Anderson JL, Karagounis LA for the TEAM-3 Study Investigators. QT interval dispersion versus reperfusion status in acute myocardial infarction. Circulation 1993; 88:I-307(1640).

    57. Kowey PR, for the IV Amiodarone Investigators. A multicenter randomized double-blind comparison of intravenous bretylium with amiodarone in patients with frequent malignant ventricular arrhythmias. Circularion 1993; I-396(2127).

    58. Stein KM, Karagounis LA, Anderson JL, Kligfield S, Lernan BB. Fractal clustering of ventricular ectopy correlates with sympathetic tone preceding ventricular ectopy. Circulation 1993, I-45 (230).

    59. Fuchs J, McCabe CH, Antman EM, Borzak S, Palisaitis D, Herson S, Daum R, Palmeri S, Sequeira R, Sharma GVRK, Diver DD, Warnica W, Mueller RM, Goldberg N, Leya F, Thompson C, Williams DO, Remetz M, Chakko S, Henry T, Hochman J, Chaitman B, Cannon CP, Findlen K, Adelman B, Braunwald E, for the TIMI 7 Investigators*. Hirulog in the treatment of unstable angina: Results of the TIMI 7 trial. J Am Coll Cardiol 1994; 56A.

    60. Anderson JL, Karagounis LA. Is IV heparin or time-to-treatment responsible for differences in GUSTO adn ISIS-3 results? J Am Coll Cardiol 1994; 28A.

    61. Moreno FL, Anderson JL, for the TEAM-2 Study Investigators*. The predictive value of QT versus JT dispersion after thrombolysis for acute myocardial infarction. J Am Coll Cardiol 1994; 178A.

    62. Stein KM, Karagounis LA, Anderson JL, Leman BB. Autonomic triggers of ventricular tachycardia in patients with repetitive monomorphic ventricular tachycardia. J Am Coll Cardiol 1994; 372A.

    63. Moreno FL, Karagounis LA, Horn SD, Anderson JL. Comparison of signal-averaging ECG systems using device-specific criteria on normal subjects. Eur J CPE June 1994; 4:888.

    64. Reiter MJ, Mann DE, Reiffel JE, Karagounis LA, Hahn E, Hartz V, and the ESVEM Investigators. Reproducibility of drug efficacy prediction by Holter monitoring in the ESVEM Trial. Circulation 1994; 90:I-961(179).

    65. Gomez MA , Anderson JL, Karagounis LA, Mooers FB, for the ROMIO Study Group. Reduced hospital time and cost using an emergency room based rapid rule-out myocardial ischemia protocol: results of the ROMIO Study, Phase I. Circulation 1994; 90:I-324(1738).

    66. Zahger D, Karagounis LA, Cercek B, Anderson JL, Sorensen SG, Moreno FL and Shah PK. Incomplete recanalization rather «no reflow» is the main determinant of TIMI-2 flow after thrombolysis: results from the TEAM studies. Circulation 1994; 90:I-220(1182).

    67. Karagounis LA, Moreno FL, Sorensen SG, Anderson JL, for the TEAM-3 study Investigators. Multivariate determinants of QT dispersion in patients with acute myocardial infarction: primacy of patency status of the infarct related artery. Circulation 1994; 90:I-662(3563).

    68. Muhlestein JB, Hammond EH, Carlquist JF, Radicke E, Thomson MJ, Parker DJ, Karagounis LA, Anderson JL. Increased incidence of chlamydia bacteria detected within coronary arteries of patients with atherosclerotic versus transplant induced coronary artery disease. J Am Coll Cardiol 1995; 291A.

    69. Cannon CP, Henry TD, Schweiger MJ, Haugland M, McKendall GR, Shah PK, Gleason R, McCabe CH, Antman EM, Braunwald E, TIMI 9 Registry Investigators and Coordinators. Current Management of ST elevation myocardial infarction and outcome of thrombolytic ineligible patients: Results of the multicenter TIMI 9 registry. J Am Coll Cardiol 1995; 231A.

    70. Karagounis LA, Anderson JL. QT dispersion predicts mortality in treated patients with life-threatening ventricular tachyarrhythmias. J Am Coll Cardiol 1995; 16A.

    71. The AVID Investigators*. Patient enrollment in the Antiarrhythmic Versus Implantable Defibrillators (AVID) Study – Pilot Phase. PACE 1995;15.

    72. Karagounis LA, Anderson JL, Hammond E, Summers KL, Swanson S, and Holland C. Correlation of endomyocardial biopsy with power spectrum indexes of heart rate variability: ratio of low to high frequency predicts cardiac rejection. PACE 1995;41.

    73. Anderson JL, Karagounis LA, Stein KM, Fidela Ll Moreno FLl, Ledingham R, Hallstrom A, for the CAST Investigators. Measures of fractal clustering of ventricular arrhythmias as predictors of arrhythmic events after myocardial infarction. PACE 1995;233.

    74. Karagounis LA, Stein KM, Afridi SN, Bair T, Albright D, Anderson JL, for the ESVEM Investigators. A fractal dimension predicts arrhythmia recurrence in patients being treated for life threatening ventricular arrhythmias. PACE 1995;225.

    75. Anastasiou-Nana MI, Karagounis LA, Anderson JL, Mason JW and the ESVEM Investigators. Variability of spontaneous ventricular ectopy in patients with life threatening ventricular arrhythmias. European Society of Cardiology. Amsterdam 1995

    76. Muhlestein JB, Gomez MA, Karagounis LA, and Anderson JL. «Rescue ReoPro»: acute utilization of abciximab for the dissolution of coronary thrombus developing as a complication of coronary angioplasty. Circulation 1995; 92:I-607(2906).

    77. Gomez MA , Anderson JL, Karagounis LA, Mooers FB, for the ROMIO Study Group. An emergency department based rapid rule-out of myocardial ischemia protocol reduces hospital time and cost: final results of a randomized study (ROMIO). Circulation 1995; 92:I-739(3549).

    78. Muhlestein JB, Bair TL, Karagounis LA, and Anderson JL. Failure of present clinical algorithms of intravenous heparin adjustment to maintain stable therapeutic anticoagulation in coronary care unit setting. J Am Coll Cardiol 1995; 332A.

    79. Nana MI, Nanas JN, Karagounis LA, Batziou C, Tsagalou E, Alexopoulos G, Margari M, Stamatelopoulos SF, and Moulopoulos SD. Interlead variation of QRS duration predicts mortality in patients with severe congestive heart failure. Submitted for the American Heart meetings.

    80. Nana MI, Nanas JN, Karagounis LA, Kouvalas N, Batziou C, Tsagalou E, Alexopoulos G, Stamatelopoulos SF, and Moulopoulos SD. Stability of heart rate variability indexes over consecutive days in patients with severe congestive heart failure. Submitted for the American Heart meetings